Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 3

1(33.3%)

Phase 1

1(33.3%)

3Total

N/A(1)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06860373Phase 3Terminated

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Role: lead

NCT06484426Completed

Goal Attainment Scaling (GAS) Sub-Study

Role: lead

NCT04149197Terminated

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

Role: lead

NCT05343468Not ApplicableCompleted

Life Skills Improved in Children With Down Syndrome After Using Assistive Technology

Role: collaborator

NCT02738450Phase 1Completed

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

Role: collaborator

All 5 trials loaded